A Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VAY736 in Rheumatoid Arthritis Patients
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs VAY 736 (Primary) ; VAY 736 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Feb 2018 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2017.
- 29 Nov 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2017.